Genmab — Oktober 2018
-
Rekruttering genoptaget i alle klinikker iADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma. https://clinicaltrials.gov/ct2/show/NCT02432235?term=adct-301&rank=3
-
Symphony Health's USD 355m for Q3. Hvad giver det for September?
-
... Eller 354,9 for at være præcis...
-
så giver det 114,9
-
sorry 114,3
-
hvis det er rigtigt er det en d/d udvikling over august måned på 11,5% - noget som vi skal helt tilbage til okt 2017 for at se
-
Hvor står det henne JS
tudsgaard? -
hvis vi regner over hele Q3, så er rabatten i US svundet ind til 10,4%
-
*JStudsgaard (sorry)
-
Jeg har fået det fra min bank...
-
dvs der er givet 3,7% mindre i rabat ifht listeprisn
-
det er faktisk ret stærkt - både ifht volumenvækst, men også ifht prisudvikling
-
tak for det Jstudsgaard
-
The average discount level has been around 10% since Q2 2017, which thus seems like a reasonable estimate going forward.
-
Dejligt at kunne give lidt tilbage
-
Tak skal du have. Underligt hvis de ikke vil melde en positiv nyhed ud.
-
@Doc4 Kommer her! Casen er intakt
Lad bare Ganske Blank forære deres guld bort... -
Tusinde tak Studsgaard. Det er pæne tal
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind